Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viscum Album with Pembrolizumab in TNBC
NCT06920810Phase 4Recruiting
- Sponsor
- Ilsan CHA Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of viscum album in triple-negative breast cancer (TNBC) (2 arms), sponsored by Ilsan CHA Hospital. Primary endpoint: Cytokine panel at week 19. Started Mar 2025; status: recruiting.
02
Drugs
viscum album
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06920810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920810.